Enteric-Coated Meta-Arsenite for Oral Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments face challenges with the toxicity of arsenic compounds when administered orally, leading to adverse side effects and limited effectiveness due to rapid oxidation in the stomach, which complicates the development of effective oral anti-cancer agents.
Innovation Solution
Development of an enteric-coated solid pharmaceutical composition comprising sodium or potassium meta-arsenite, with a specific formulation and enteric coating that minimizes oxidation and allows for targeted release in the small intestines, where acidity is between pH 6.5-7.5, using pharmaceutically acceptable excipients and an enteric polymer coating.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If arsenic compounds are administered orally, then ease of administration and patient compliance are improved, but toxicity and adverse side effects worsen due to rapid oxidation in the stomach
Solution Approach 1:
The patent applies preliminary action by pre-coating the arsenic compound core with an enteric coating before administration. This coating is designed to resist dissolution in the acidic stomach environment (pH 1.2-3.0) and only dissolve in the more neutral environment of the small intestine (pH 6.5-7.5), thereby preventing premature oxidation and toxicity while maintaining ease of oral administration
Solution Approach 2:
The enteric coating acts as an intermediary barrier between the arsenic compound and the stomach environment. This intermediate layer protects the arsenic compound from acidic conditions and oxidation in the stomach, allowing it to reach the small intestine intact where it can then dissolve and exert its therapeutic effect without causing systemic toxicity
2Object-affected harmful factors
If enteric coating is applied to protect arsenic compounds, then oxidation and toxicity are reduced, but device complexity and manufacturing difficulty increase
Solution Approach 1:
The patent applies parameter changes by formulating the enteric coating with specific polymers (such as cellulose acetate phthalate, hydroxypropyl methylcellulose phthalate, or polyvinyl acetate phthalate) that have defined dissolution characteristics at specific pH ranges. The coating is designed to remain intact at pH 1.2-3.0 (stomach) and dissolve at pH 6.5-7.5 (small intestine), using controlled changes in environmental parameters to achieve protection without excessive complexity
3Ease of operation
If oral formulation is developed for cancer treatment, then patient compliance and quality of life are improved, but therapeutic effectiveness worsens due to rapid oxidation in the stomach
Solution Approach 1:
The enteric coating is applied in advance to protect the arsenic compound during gastric transit, ensuring that the active ingredient reaches the small intestine in its reduced, non-oxidized form where it can be effectively absorbed and exert its anti-cancer therapeutic effect, thereby maintaining both patient compliance and therapeutic effectiveness
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The enteric-coated composition effectively reduces the risk of oxidation and toxicity, enabling stable and controlled release of arsenic compounds, enhancing their therapeutic efficacy and safety for oral administration in cancer treatment.
Implementation Method 1
one or more pharmaceutically acceptable excipients are selected such that oxidation of meta-arsenite to meta-arsenate is minimised
Implementation Method 2
passes through the stomach and commences dissolution in the small intestines (where acidity is between pH 6.5-7.5)
Data Source
AI summary
The present application relates to pharmaceutical compositions comprising a salt of arsenous acid, such as sodium meta arsenite or potassium meta arsenite, and methods of manufacturing the pharmaceutical compositions.